1. Home
  2. APWC vs RLYB Comparison

APWC vs RLYB Comparison

Compare APWC & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

APWC

Asia Pacific Wire & Cable Corporation Ltd. (Bermuda)

HOLD

Current Price

$1.42

Market Cap

65.3M

Sector

Industrials

ML Signal

HOLD

Logo Rallybio Corporation

RLYB

Rallybio Corporation

HOLD

Current Price

$14.00

Market Cap

75.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APWC
RLYB
Founded
1996
2018
Country
Taiwan
United States
Employees
N/A
14
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
65.3M
75.9M
IPO Year
1997
2021

Fundamental Metrics

Financial Performance
Metric
APWC
RLYB
Price
$1.42
$14.00
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
6.8K
289.2K
Earning Date
04-29-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$858,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$12.60
N/A
Revenue Growth
N/A
43.00
52 Week Low
$1.27
$0.27
52 Week High
$2.34
$15.31

Technical Indicators

Market Signals
Indicator
APWC
RLYB
Relative Strength Index (RSI) 46.20 80.20
Support Level $1.28 $0.54
Resistance Level $1.47 $15.31
Average True Range (ATR) 0.06 0.71
MACD -0.01 0.23
Stochastic Oscillator 12.50 83.84

Price Performance

Historical Comparison
APWC
RLYB

About APWC Asia Pacific Wire & Cable Corporation Ltd. (Bermuda)

Asia Pacific Wire & Cable Corp Ltd is a holding company. It is principally engaged in the manufacture and distribution of enameled wire, power cable, and telecommunications products in Thailand, Singapore, Australia, PRC, Hong Kong and certain other markets in the Asia Pacific region. It also provides project engineering services in the supply, delivery and installation of power cables (SDI). Some of the company's products are Bare wires, Power cables, Communication cables, Electronic wires & cables, and Enamelled wires. The company's geographical segments are North Asia, Thailand, and Rest of the World.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Share on Social Networks: